Growth Hormone AxisIn StockGrowth Hormone Axis
Ipamorelin
Also known as: NNC 26-0161, Selective GHS-R1a agonist
Selective synthetic pentapeptide ghrelin-receptor agonist widely used in growth-hormone-secretagogue research.
Ipamorelin is a synthetic pentapeptide and one of the most selective known agonists of the growth-hormone-secretagogue receptor (GHS-R1a), also referred to as the ghrelin receptor.
It was developed by Novo Nordisk in the 1990s as part of a program to identify GH-releasing compounds with a minimal off-target effect profile.In the preclinical literature, Ipamorelin is notable for its receptor selectivity — published studies indicate minimal effect on ACTH, cortisol, prolactin, FSH, LH, and TSH in the tested models.
This selectivity has made it a reference compound in research comparing the various growth hormone secretagogues.Ipamorelin is among the highest-volume research peptides in its class, frequently paired with GHRH analogs like CJC-1295 (no DAC) and Sermorelin in combination-signaling research.
Research applications
- GHS-R1a (ghrelin receptor) pharmacology
- Selective GH secretagogue research
- Combination signaling with GHRH analogs
- Gastric-motility and ghrelin-pathway biology
- Comparative pharmacology vs. GHRP-2/GHRP-6
Technical profile
- Net content
- 10 mg
- Molecular formula
- C38H49N9O5
- Molecular weight
- 711.85 g/mol
- CAS
- 170851-70-4
- Sequence
- Aib-His-D-2-Nal-D-Phe-Lys-NH2
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates GH release from the pituitary without significantly affecting cortisol or prolactin levels, making it one of the most selective GH-releasing peptides available.
